Results from the Trifecta Study: Combining Fraction and Estimated Amount of dd-cfDNA to Assess Kidney Transplant Rejection
Watch Video
Watch Video
Read Article
Read Flipbook
Read Flipbook
Read Article
Reusing, et al. 2022, Transplant Proceedings
Read Flipbook
Ventura-Aguiar, et al. 2022, Transplantation
Read Flipbook
Watch Video
Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection with great precision.
Read Flipbook
Watch Video
Rodolfo R. Batarsé, MD, FASN Community Nephrologist
Watch Video
Read Flipbook
The Prospera non-invasive blood test can comprehensively identify all types of active rejection with great precision.
Read Flipbook
Prospera uses revolutionary tech to enhance the patient and physician’s ability to assess otherwise undetected rejection events that might lead to kidney loss.
Read Flipbook
Natera welcomes all insurance plans. We’re here with you at every step.
Read Flipbook
Listen
With Natera’s precise DNA analysis, you can effectively manage and provide the best available care to all your kidney patients.
Read Flipbook
Read Flipbook
Watch Video
The Prospera non-invasive blood test can comprehensively identify all types of active rejection with great precision.
Read Flipbook
Loading More...